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Liver transplant recipients have an increased risk of malignancy. Smoking is related to some of the most frequent causes of
posttransplant malignancy. The incidence and risk factors for the development of neoplasia related to smoking (head and
neck, lung, esophageal, and kidney and urinary tract carcinomas) were studied in 339 liver transplant recipients. Risk fac-
tors for the development of smoking-related neoplasia were also studied in 135 patients who had a history of smoking so
that it could be determined whether smoking withdrawal was associated with a lower risk of malignancy. After a mean fol-
low-up of 7.5 years, 26 patients were diagnosed with 29 smoking-related malignancies. The 5- and 10-year actuarial rates
were 5% and 13%, respectively. In multivariate analysis, smoking and older age were independently associated with a
higher risk of malignancy. In the smoker subgroup, the variables related to a higher risk of malignancy were active smoking
and older age. In conclusion, smoking withdrawal after liver transplantation may have a protective effect against the devel-
opment of neoplasia. Liver Transpl 17:402-408, 2011. VC 2011 AASLD.
Received July 22, 2010; accepted December 6, 2010.
One of the most important consequences of immuno-
suppression is the risk of de novo malignancies1 due
to the loss of immunovigilance. Thus, liver transplant
recipients have an increased risk of neoplasia in com-
parison with the general population.2-5 In fact, neo-
plasia is one of the most frequent causes of late mor-
tality in adult liver transplant recipients.1,6
Smoking is a well-known risk factor for the develop-
ment of neoplasia both in the general population and in
liver transplant recipients.1,3,7 It is mainly related to
lung,8,9 upper aerodigestive tract, and urinary tract carci-
nomas.10,11 As a result, active smokers after transplanta-
tion have a higher risk of malignancy than nonsmokers.12
The aim of this study was to investigate the risk fac-
tors for lung, head and neck, esophageal, and kidney
and urinary tract carcinomas (excluding prostate car-
cinoma) after liver transplantation. In addition, we
investigated whether the risks of developing one of
these malignancies were different in patients who
ceased smoking and in patients who continued smok-
ing after transplantation.
PATIENTS AND METHODS
Patients
We analyzed all adult patients who underwent liver
transplantation for the first time between April
1990 and December 2009 and survived more
than 3 months after transplantation. They received
Abbreviation: SRM, smoking-related malignancy.
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cyclosporine- or tacrolimus-based immunosuppres-
sion, as previously described.13
Follow-Up
All liver transplant candidates underwent urinalysis,
a chest X-ray examination, an abdominal ultrasound
examination, and gastroscopy when they were eval-
uated as candidates for transplantation. Furthermore,
patients with a smoking history greater than 20 pack-
years who were actively smoking or had quit smoking
less than 10 years before underwent a computed to-
mography scan of the chest and an ear-nose-throat
evaluation to rule out malignancy.
The frequency of the follow-up and the studies for ne-
oplasia screening after transplantation are described in
a recently published article.14 Our group has intro-
duced a screening protocol based on the risk of neopla-
sia of every patient. With respect to the neoplasia stud-
ied in this study, all patients underwent urinalysis, a
chest X-ray examination, and an abdominal ultrasound
examination every year. Patients with a smoking history
greater than 20 pack-years who were actively smoking
or had quit smoking less than 10 years before were
seen every year in the ear-nose-throat outpatient clinic
(since 2000) and underwent a low-radiation computed
tomography scan of the chest every year (since 2006).
A smoking history was obtained when patients were
referred for transplantation. Smoking cessation was
recommended to smokers. After transplantation,
patients were asked about their smoking behavior at
least 4 times within the first posttransplant year and
once a year thereafter.
Definitions
Smoking-related malignancies (SRMs) included de
novo lung, head and neck, esophageal, and kidney
and urinary tract carcinomas (excluding prostate
carcinoma).
The smoking status was classified as follows:
• Nonsignificant smokers: patients who did not
have a past history of smoking, who had a history
of smoking less than 20 pack-years, or who had
ceased smoking more than 10 years before
transplantation.
• Previous smokers: patients with a past history of
smoking greater than 20 pack-years who had
ceased smoking less than 10 years before trans-
plantation or immediately after transplantation
and did not resume smoking after
transplantation.
• Active smokers: patients with a history of smok-
ing greater than 20 pack-years who continued
smoking after transplantation.
Description of the Study
The relative risks of developing lung cancer, head and
neck cancer, esophageal cancer, and kidney and uri-
nary tract cancer (excluding prostate cancer) were
obtained through a comparison of the number of
observed cases and the number of cases expected
according to age- and sex-based rates of neoplasia
and cancer mortality rates for Navarra (Spain) in
1998-2002.15
The relative risks of developing SRM and dying from
SRM were obtained in a similar way. Similarly, the
relative risks of developing SRM were calculated for
each subgroup of patients: nonsmokers, previous
smokers, and active smokers.
The following potential risk factors for the develop-
ment of SRM were studied: age, sex, alcohol abuse (ie,
alcohol consumption > 80 g/day for >10 years) before
liver transplantation, hepatitis C virus infection, he-
patocellular carcinoma at transplantation, primary
immunosuppression (cyclosporine or tacrolimus), his-
tory of rejection requiring high doses of steroids or
anti-lymphocyte globulins in the first 3 months, num-
ber of immunosuppressive drugs at 3 months, and
smoking history (nonsignificant smokers versus active
or previous smokers). A second analysis of risk factors
for the development of SRM was performed only for
smokers. In this second study, the same potential
risk factors were studied, but smoking was studied in
terms of active smokers and previous smokers.
The study was revised and approved by the institu-
tional review board of the University of Navarra and by
the Spanish Agency for Drugs and Sanitary Products.
Statistical Analysis
For statistical analysis, the Statistical Package for the
Social Sciences, version 15.0 (SPSS, Inc., Chicago, IL),
was used. Patients who developed SRMs during fol-
low-up were compared with the rest of the patients.
The distribution of categorical variables was com-
pared with the chi-square test or Fisher’s exact test
(whichever was appropriate). Differences between
means were assessed with the Student t test or the
Mann-Whitney U test. The Kaplan-Meier method was
used to obtain survival rates and rates of neoplasia.
Comparisons between groups were performed with
the log-rank test. The potential influence of a continu-
ous variable on the risk of developing SRM was stud-
ied with Cox regression analysis. The primary variable
(smoking) and the variables with a P value < 0.2 in
univariate analysis were included in a Cox regression
analysis.
The relative risks of neoplasia and neoplasia-related
mortality were obtained through a comparison of the
number of observed cases and the number of
expected cases. The 95% confidence limits for the rel-
ative risks (observed-to-expected ratios) were obtained
after a Poisson distribution was assumed for cancer
rates and rates of cancer-related mortality.
RESULTS
Characteristics of the Patients
In the studied period, 356 adult patients received
their first liver graft at our center. Fourteen patients
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were excluded because they died before the third
posttransplant month. In none of them was a malig-
nancy diagnosed before death or at the autopsy.
Another 3 patients were excluded from the study
because they underwent combined hepatorenal trans-
plantation (2 patients) or had a human immunodefi-
ciency virus infection (1 patient). The general charac-
teristics of the 339 patients included in the study are
shown in Table 1. The mean follow-up of the patients
was 7.5 years. Patients were followed for a total of
2533 patient-years.
Risk of SRM
Twenty-six patients were diagnosed with 29 SRMs: 9
patients had lung cancer, 8 had head and neck can-
cer, 3 had esophageal cancer, and 9 had kidney or
urinary tract cancer. Their risks are shown in Fig. 1.
The 5- and 10-year SRM rates were 5% and 13%,
respectively. Data about their stages at diagnosis and
outcomes are shown in Table 2.
Evolution After the Diagnosis of SRM
Fifteen (57.7%) of the patients with SRMs had died by
the end of follow-up; in 13 cases, their deaths were
due to SRMs. The median survival of the patients af-
ter the diagnosis of SRM was 2 years. The 1-, 2-, and
3-year survival rates after the diagnosis of SRM were
75%, 50%, and 40%, respectively. SRMs were the
causes of death for 45% of the patients who died of de
TABLE 1. Comparative Features of 26 Liver Transplant
Recipients With De Novo SRMs and 313 Patients
Without SRMs
Feature
Without
SRM
With
SRM P Value
Age (years), mean
(standard deviation)
55.56
(9.87)
60.06
(6.60)
0.004
Sex (male/female), % 76/24 96.2/3.8 0.009
Hepatitis C, % 32.6 11.5 0.017
Hepatocellular
carcinoma, %
38.3 34.6 > 0.2
Child-Pugh status, % 0.085
A 20.5 11.5
B 47 34.6
C 32.6 53.8
Alcohol abuse, % 37.1 61.5 0.013
Smoking, % <0.001
Nonsignificant 64.5 7.7
Previous 17.2 34.6
Active 18.2 57.7
Primary immunosuppression, % >0.2
Cyclosporine 38 34.6
Tacrolimus 62 65.4
Treated rejection, % 16.9 3.8 0.08
Number of immunosuppressive
drugs at 3 months, %
0.042
1 13.4 30.8
2 37.7 23.1
3 48.9 46.3
NOTE: SRMs included lung, head and neck, esophageal,
and kidney and urinary tract carcinomas.
Figure 1. Risk of SRM (lung, head and neck, esophageal, and
kidney and urinary tract cancers) in 339 liver transplant
recipients.
TABLE 2. Diagnosed SRMs (Including Their Stages)
and Patients’ Current Status and Survival After the
Diagnosis
SRM
Stage at
Diagnosis
Current Status
and Survival
Lung I: 5 patients Alive, 27 and
30 months;
dead, 9, 15, and
26 months
III: 2 patients Dead, 2 and
14 months
IV: 2 patients Dead, 7 and
24 months
Head and
neck
I: 2 patients Alive, 63 and
115 months
III: 1 patient Dead, 24 months
IV: 5 patients Dead, 2, 3, 9, 11,
and 12 months
Esophagus II: 3 patients Alive, 123 months;
dead, 16 and
32 months
Kidney and
urinary tract
0: 4 patients Alive, 4, 60, and
74 months;
dead, 71 months
I: 3 patients Alive, 64 and
92 months;
dead, 9 months
II: 1 patient Alive, 10 months
IV: 1 patient Dead, 12 months
NOTE: Twenty-six of 339 patients were diagnosed with
SRMs.
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novo malignancies and for 13.5% of the patients in
the global series.
Relative Risk of SRMs
The rates of head and neck, esophageal, and kidney
and urinary tract carcinomas were significantly higher
in this series of liver transplant recipients versus the
general population. The relative risk of lung cancer
was greater than 2, but it did not reach significance
(Table 3).
The cumulative risk of SRM was also significantly
higher in the patients versus a sex- and age-matched
general population. Nonsignificant smokers did not
have an increased risk, but active and previous smok-
ers did have a higher risk (Table 4). Mortality due to
SRM was also significantly higher in liver transplant
recipients versus the general population.
Risk Factors of SRM
In univariate analysis, alcohol abuse, significant smok-
ing, higher age, male sex, and immunosuppression
with tacrolimus were related to a higher risk of develop-
ing SRM, and hepatitis C, rejection, and a higher num-
ber of immunosuppressive drugs at 3 months were
related to a lower risk of SRM (Table 5). In multivariate
analysis, only significant smoking and a higher age
were independently associated with a higher risk of
SRM. Figure 2 shows the risk of SRM in smokers and
nonsignificant smokers.
In the smoker group (previous smokers and active
smokers), active smoking and older age were the only
2 factors independently related to the diagnosis of
SRM (Table 6). Figure 3 shows the risk of developing
SRM according to age (60 years or <60 years) and
TABLE 4. Observed and Expected Cases and Relative
Risks of Developing and Dying of SRMs According to
Smoking Status Among 339 Liver Transplant Recipients
Versus a Sex- and Age-Matched General Population
Observed
Cases (n)
Expected
Cases (n)
Relative
Risk (95%
Confidence
Interval)
SRM 29 9.568 3.03
(2-03-4-35)
SRM in
nonsignificant
smokers
2 5.543 0.36
(0.24-5.57)
SRM in
previous
smokers
8 1.803 4.44
(1.92-8.74)
SRM in active
smokers
19 2.222 8.55
(3.45-15.76)
Mortality due
to SRM
13 5.383 2.41
(1.29-4.13)
NOTE: SRMs include lung, head and neck, esophageal,
and kidney and urinary tract carcinomas (excluding
prostate carcinoma). Smoking terms are defined in the
main text.
TABLE 5. Risk Factors for the Development of Head
and Neck, Lung, Esophageal, and Kidney and Urinary
Tract Carcinomas in 339 Adult Liver Transplant
Recipients
Risk Factor
Hazard Ratio
(95% Confidence Interval)
Univariate Multivariate
Tacrolimus-based
immunosuppressive
drugs (versus
cyclosporine)
2.36
(1.03-5.42)
1.00
(0.35-2.89)
Rejection 0.14
(0.02-1.01)
0.30
(0.04-2.39)
Number of
immunosuppressive
drugs (3 months)
0.67
(0.41-1.11)
0.99
(0.52-1.87)
Alcohol* 2.76
(1.22-5.96)
0.89
(0.36-2.24)
Hepatitis C 0.29
(0.09-0.97)
0.35
(0.09-1.35)
Male sex 9.06
(1.23-66.90)
0.56
(0.06-4.75)
Age (years) 1.07
(1.02-1.12)
1.09
(1.03-1.15)
Significant
smoking†
21.90
(5.17-92.73)
19.17
(4.17-88.10)
*The patient’s alcohol consumption was greater than 80
g/day for more than 10 years.
†The patient had a past history of smoking greater than
20 pack-years and continued smoking after
transplantation or ceased smoking less than 10 years
before transplantation.
TABLE 3. Observed and Expected Cases of Lung, Head
and Neck, Esophageal, and Kidney and Urinary Tract
Carcinomas (Excluding Prostate Carcinoma) Among 339
Liver Transplant Recipients Versus a Sex- and Age-
Matched General Population
Neoplasia
Origin
Observed
Cases (n)
Expected
Cases (n)
Relative
Risk (95%
Confidence
Interval)
Lung 9 4.142 2.17
(0.99-4.12)
Head and
neck
8 2.312 3.46
(1.49-6.82)
Esophagus 3 0.379 7.91
(1.63-23.13)
Kidney and
urinary tract
9 2.722 3.31
(1.51-6.28)
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posttransplant smoking in patients who had smoked
before transplantation.
DISCUSSION
The most relevant finding of this study is that liver
transplant recipients who quit smoking had a lower
rate of SRM than patients who continued to smoke.
This finding could be very important for reinforcing
the recommendation of smoking cessation to liver
transplant candidates.
Malignancy is one of the most frequent causes of
death in liver transplant recipients,1,6 and SRMs are
some of the most frequent malignancies.3-5,7,16-18 In
fact, in the present series, SRMs were the cause of
death for 13.5% of the deceased patients. Accordingly,
the association between posttransplant malignancy
and smoking has been previously reported,1,3,7,9,12
although other authors have not found a higher risk
of neoplasia in smokers.19
Other complications associated with smoking are
increased risks of infection,19 hepatic artery thrombo-
sis and stenosis,20 and biliary complications.21 Fur-
thermore, smoking is also a risk factor for cardiovas-
cular disease,19,22 and this is one of the most
frequent causes of late mortality after liver transplan-
tation.6 With this scenario, if the findings of this arti-
cle are confirmed in larger series, all liver transplant
candidates should be counseled against smoking.
Because smokers have an increased risk of malig-
nancy, they could also benefit from surveillance proto-
cols promoting the early diagnosis of neoplasia at a
potentially curable stage. Early experiences with such
protocols have shown promising results.5,14 The pres-
ent series is underpowered to evaluate the effect of
our surveillance protocols, but a potential benefit
could be suggested. Most kidney and urinary tract
carcinomas were diagnosed at early stages: 4 at stage
0, 3 at stage I, 1 at stage II, and only 1 at stage IV.
Before the initiation of a specific surveillance protocol
for head and neck cancer, both patients with this neo-
plasia were diagnosed at stage IV. Since the initiation
of this protocol, 2 patients were diagnosed at stage I,
1 was diagnosed at stage III, and 3 were diagnosed at
stage IV. Finally, before 2006, lung cancers were
TABLE 6. Risk Factors for the Development of Head
and Neck, Lung, Esophageal, and Kidney and Urinary
Tract Carcinomas in 125 Adult Liver Transplant
Recipients With a History of Significant Smoking
Risk Factor
Hazard Ratio (95% Confi-
dence Interval)
Univariate Multivariate
Tacrolimus-based
immunosuppressive
drugs (versus
cyclosporine)
2.66
(1.07-6.63)
1.88
(0.58-6.09)
Rejection 0.22
(0.03-1.66)
0.26
(0.03-2.20)
Number of
immunosuppressive
drugs (3 months)
0.70
(0.43-1.16)
1.11
(0.55-2.23)
Alcohol* 1.73
(0.76-3.95)
1.05
(0.39-2.83)
Hepatitis C 0.40
(0.12-1.34)
0.48
(0.18-1.99)
Age (years) 1.09
(1.03-1.15)
1.13
(1.05-1.20)
Persistent smoking 1.41
(0.60-3.29)
4.00
(1.42-11.25)
*The patient’s alcohol consumption was greater than 80
g/day for more than 10 years.
Figure 2. Risk of SRM (lung, head and neck, esophageal, and
kidney and urinary tract cancers) in 339 liver transplant recipients
according to their smoking status before transplantation.
Figure 3. Risk of SRM (lung, head and neck, esophageal, and
kidney and urinary tract cancers) in 135 liver transplant
recipients who smoked before transplantation according to their
age at transplantation (>60 years or <60 years) and their
smoking status after transplantation.
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diagnosed at stages IB (1 patient), III (2 patients), and
IV (1 patient). Since 2006, 4 patients were diagnosed
at stage IA, and 1 patient was diagnosed at stage IV.
Because immunosuppression is presumably the main
risk factor for the increased risk of malignancy in trans-
plant patients, several authors have suggested that a
longer duration of immunosuppressive treatment2 or
stronger immunosuppression could be related to a
higher risk of malignancy.16,23 In our series, we have not
found such an association: in univariate analysis, tacro-
limus was associated with a higher risk of malignancy,
but this difference was not shown in multivariate analy-
sis. Surprisingly, patients who required antirejection
therapy and those who received a higher number of
immunosuppressive drugs at 3 months tended to have a
lower risk of SRM. This unexpected finding could be due
to the association between age and the development of
SRM: young patients have a lower risk of malignancy but
have a higher risk of rejection,24,25 and as a result, they
receive stronger immunosuppression. In fact, the only 2
variables that were associated with SRM in this series
were age and smoking. This is not surprising because
these 2 risk factors have been shown to be related to
malignancy both in the general population and in liver
transplant recipients.1,3,4,7
The main limitation of the study is that smoking
has been considered as a categorical variable. There-
fore, it was not possible to evaluate whether the rela-
tion between smoking and malignancy in liver trans-
plant recipients has a cumulative dosing effect. A
higher cumulative dose of smoking could also explain
in part the association between older age and SRM
because older patients may have a higher cumulative
dose of smoking. Unfortunately, it was not possible to
obtain more detailed data about the past history of
smoking because this is a retrospective study.
Another limitation of the study is the low number of
cancer events, which limits the multivariate analysis.
Therefore, these findings must be confirmed in larger
series or multicenter studies.
In conclusion, smoking withdrawal after liver trans-
plantation may have a protective effect against the de-
velopment of neoplasia. Because smoking is an im-
portant risk factor of malignancy, intervention
programs, together with screening programs, may
help us to reduce the rate of cancer-related mortality
in liver transplant recipients.
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